This also holds true for BCL2i combination with the dual-inhibitor of HDACs and PI3K, CUDC-907 (fimepinostat) [152,153], which is currently under efficiacy and safety evaluation in a phase I clinical trial in R/R DLBCL (NCT01742988). This evidence concerns the gene PIK3CD and diffuse large B-cell lymphoma.